The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - ESMO
Efficacy and toxicity of antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review.
 
Tiago Costa de Padua
No Relationships to Disclose
 
Greta Malena
No Relationships to Disclose
 
Marco Moschini
No Relationships to Disclose
 
Alberto Martini
No Relationships to Disclose
 
Laura Marandino
Research Funding - AstraZeneca
 
Daniele Raggi
No Relationships to Disclose
 
Alberto Briganti
No Relationships to Disclose
 
Francesco Montorsi
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)